Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
Chiara OriecuiaDaniela TomasoniIsabella SalaGiovanni Battista BonfioliMarianna AdamoCristina GussagoCarlo Mario LombardiMatteo PagnesiGianluigi SavareseMarco MetraClaudia SpecchiaPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
Among patients with HF, irrespective of their LVEF and clinical status, the addition of SGLT2i to SOC demonstrated a significant improvement in quality of life as early as at 3-month follow-up.
Keyphrases